# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these i...
Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $155 price target.
Merck discontinues two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, for Keytruda in lung cancer and cutaneous squamous cell car...
. This decision is based on the recommendation of an independent Data Monitoring Committee (DMC), which reviewed data from a pl...
The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors...